{"product_id":"dtil-ansoff-analysis","title":"(DTIL) Precision BioSciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Precision BioSciences, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification to guide research, investing, or strategic planning. This page includes a real preview of the analysis so you can review style and substance before buying; purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR0191 Phase 1\/2a in adult R\/R NHL and R\/R B-ALL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences is using PBCAR0191, its existing allogeneic CAR T asset, in the same Phase 1\/2a blood-cancer setting: adult relapsed\/refractory non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. \u003c\/p\u003e\n\u003cp\u003eThis is market penetration, not a new market push, so the goal is sharper execution in a known oncology niche. \u003c\/p\u003e\n\u003cp\u003eBetter clinical data can lift confidence, improve physician uptake, and strengthen positioning in current CD19-targeted markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR19B anti-CD19 single-step gene edit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCAR19B is a classic market penetration play: it stays in the CD19 CAR T field and aims to win share by improving a known target, not by opening a new market. Its single-step gene edit and stealth cell design are meant to lower chromosomal abnormality risk, which can sharpen its profile versus standard CD19 assets.\u003c\/p\u003e\n\u003cp\u003eThis matters in a market already defined by intense CD19 competition, where even small safety gains can sway use in relapsed or refractory B-cell cancers. Precision BioSciences, Inc. is using differentiation inside an existing segment to push adoption, which fits Ansoff's penetration logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARCUS platform leadership in genome editing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARCUS is Precision BioSciences, Inc.'s proprietary genome editing platform, so this is a clear market penetration play: it strengthens the same technical base that supports the Company’s current gene-editing work instead of pushing into a new market.\u003c\/p\u003e\n\u003cp\u003eThat focus helps Precision BioSciences, Inc. build credibility with existing scientific and clinical users, which can deepen adoption across its current pipeline and partner set.\u003c\/p\u003e\n\u003cp\u003eIn 2025, the key value is tighter execution around one core platform, not category expansion; that is usually the fastest way to gain share in an existing niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePBCAR269A in R\/R multiple myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePBCAR269A pushes Precision BioSciences, Inc. deeper into the BCMA-positive relapsed\/refractory multiple myeloma market, a blood-cancer field with about 35,000 U.S. cases a year. It keeps the same allogeneic CAR T logic, so market penetration comes from a second high-value hematology use case, not a new platform. That can broaden relevance across the current oncology buyer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame allogeneic CAR T platform\u003c\/li\u003e\n\u003cli\u003eTargets BCMA-positive myeloma\u003c\/li\u003e\n\u003cli\u003eFits hematologic oncology buyers\u003c\/li\u003e\n\u003cli\u003eExpands presence in a large segment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eServier alliance for allogeneic CAR T development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServier gives Precision BioSciences a wider route to market for its allogeneic CAR T programs, extending development and commercialization across oncology targets already in scope. This is market penetration: it pushes current assets deeper through a stronger partner network, while keeping the core business unchanged. The alliance also helps scale execution without adding a new business line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands reach for current CAR T assets\u003c\/li\u003e\n\u003cli\u003eSupports oncology targets already in focus\u003c\/li\u003e\n\u003cli\u003eStrengthens execution through Servier\u003c\/li\u003e\n\u003cli\u003eFits market penetration, not diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Doubles Down on Blood-Cancer Niches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. is using its current ARCUS and allogeneic CAR T base to win more share in known blood-cancer niches, not to enter a new market. PBCAR0191 and PBCAR19B stay in CD19 disease, and PBCAR269A stays in BCMA myeloma, so the play is deeper penetration through better fit, safety, and execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\/2026 focus\u003c\/th\u003e\n\u003cth\u003eMarket signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR0191\u003c\/td\u003e\n\u003ctd\u003er\/r NHL and B-cell precursor ALL\u003c\/td\u003e\n\u003ctd\u003eSame CD19 niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR19B\u003c\/td\u003e\n\u003ctd\u003eCD19 CAR T\u003c\/td\u003e\n\u003ctd\u003eSharper differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR269A\u003c\/td\u003e\n\u003ctd\u003eBCMA-positive r\/r multiple myeloma\u003c\/td\u003e\n\u003ctd\u003eAbout 35,000 U.S. cases a year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Precision BioSciences, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise Precision BioSciences Ansoff Matrix for quick growth strategy alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, financial, and peer-reviewed sources to validate each Ansoff growth path for Precision BioSciences, enabling fast, traceable due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier expansion into solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier’s agreement extends Precision BioSciences’ allogeneic CAR T platform from hematologic cancers into solid tumors, so this is clear market development. Solid tumors are a much larger oncology pool than blood cancers, which had about 10.0 million new cases worldwide in 2022, versus about 1.3 million leukemia, lymphoma, and myeloma cases combined. The move broadens Precision’s addressable market without changing the core cell-therapy approach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier expansion beyond CD19 targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier expansion beyond CD19 broadens Precision BioSciences, Inc.’s market development into new hematologic cancer submarkets while keeping the same CAR T platform. The same ARCUS-based architecture can be reused for new antigens, so one technical base can serve more patient groups and raise addressable demand. In 2025, CD19 CAR T therapies remained a multibillion-dollar market, and adding non-CD19 targets is a direct path to wider pipeline reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiECURE collaboration for ARCUS-based gene editing therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences’ iECURE deal pushes ARCUS into more gene-editing therapy programs, so this is market development: the same platform now serves settings beyond the Company’s CAR T oncology work. One partnership, two therapeutic lanes, and a wider addressable market for ARCUS. It also broadens Precision BioSciences’ reach into non-oncology gene editing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTiziana foralumab as a lymphodepleting agent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Tiziana foralumab work fits Precision BioSciences, Inc.'s Market Development move by opening a new use case around lymphodepletion before cell therapy, especially CAR T. In CAR T, lymphodepletion with fludarabine and cyclophosphamide is standard, and Precision BioSciences, Inc. could use that setting to widen clinical utility beyond its core editing programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew combo setting for CAR T support\u003c\/li\u003e\n\u003cli\u003eExpands use beyond single-agent therapy\u003c\/li\u003e\n\u003cli\u003eTargets a high-value oncology workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePBCAR269A in BCMA-positive multiple myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePBCAR269A is a market development move for Precision BioSciences, because it uses the same allogeneic CAR T platform in BCMA-positive relapsed or refractory multiple myeloma, a new hematologic segment beyond CD19. BCMA is already clinically validated, with 2 U.S.-approved BCMA CAR-Ts, and later-line RRMM still has poor outcomes, with median overall survival near 1 to 2 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew cancer segment: BCMA-positive multiple myeloma\u003c\/li\u003e\n\u003cli\u003eSame platform, broader oncology reach\u003c\/li\u003e\n\u003cli\u003eCompetes in an approved CAR-T market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Widens Its CAR T Reach Beyond Blood Cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc.’s market development is clear in Servier’s expansion into solid tumors and new CAR T targets: it keeps the ARCUS\/allogeneic CAR T core, but opens larger patient pools. Solid tumors had about 19.3 million new cases in 2022, far above the ~1.3 million leukemia, lymphoma, and myeloma cases combined. That widens demand without changing the platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eServier expansion\u003c\/td\u003e\n\u003ctd\u003eSolid tumors\u003c\/td\u003e\n\u003ctd\u003eSame platform, new oncology segment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCMA program\u003c\/td\u003e\n\u003ctd\u003eRRMM\u003c\/td\u003e\n\u003ctd\u003eSame CAR T base, new antigen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003ePrecision BioSciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR19B stealth cell anti-CD19 candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCAR19B fits Product Development in the Ansoff Matrix: Precision BioSciences is refining an existing CAR T asset for the CD19 market with a single-step ARCUS edit. The design aims to lower chromosomal abnormality risk, a clear next-gen safety upgrade versus older multi-edit approaches. In 2025, the CAR T field still had 6 approved CD19\/BCMA products, so sharper safety can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCAR269A BCMA-targeted allogeneic CAR T\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCAR269A is Precision BioSciences, Inc.'s BCMA-targeted allogeneic CAR T candidate, and it is direct product development for multiple myeloma. It expands the pipeline beyond CD19 and builds a second major allogeneic CAR T franchise. That matters because BCMA is a proven myeloma target, so this is a clear move into a larger adjacent market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARCUS-based gene editing therapies with iECURE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe iECURE collaboration helps Precision BioSciences turn its ARCUS genome-editing platform into new therapeutic assets, so this is product development. It adds pipeline depth without changing the core platform, which fits Ansoff’s \"new products, current capability\" path. One deal can extend reach across rare-disease programs and raise the odds that platform science becomes commercial value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAllogeneic CAR T therapies under Servier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Servier deal signals a move into new product generation: Precision BioSciences, Inc. is helping develop allogeneic CAR T therapies across multiple antigen targets, so this is broader than one asset. That fits Ansoff’s product development path, since the company is adding new CAR T constructs to its cell therapy pipeline rather than only extending one existing candidate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds multiple allogeneic CAR T programs\u003c\/li\u003e\n\u003cli\u003eExpands the cell therapy pipeline\u003c\/li\u003e\n\u003cli\u003eTargets more than one antigen\u003c\/li\u003e\n\u003cli\u003eUses Servier to de-risk development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eForalumab-enabled cancer treatment regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTesting foralumab as a lymphodepleting agent is a product-development move for Precision BioSciences, Inc. It adds a 2nd therapy layer around future CAR T regimens, aiming to improve T-cell expansion and response depth. Lymphodepletion is already a standard prep step before CAR T, so this combo concept is clinically direct.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew combo-treatment concept\u003c\/li\u003e\n\u003cli\u003eSupports future CAR T performance\u003c\/li\u003e\n\u003cli\u003eFits product development, not market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Expands CAR T with Better Safety and New Targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. uses Product Development by upgrading existing CAR T science into new assets: PBCAR19B refines CD19 safety, PBCAR269A adds a BCMA program, and iECURE and Servier extend the ARCUS platform into more therapies. In 2025, the CD19\/BCMA CAR T market already had 6 approved products, so better safety and more targets matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR19B\u003c\/td\u003e\n\u003ctd\u003eCD19 CAR T\u003c\/td\u003e\n\u003ctd\u003eRefinement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBCAR269A\u003c\/td\u003e\n\u003ctd\u003eBCMA CAR T\u003c\/td\u003e\n\u003ctd\u003eAdjacent growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003e6 approved products\u003c\/td\u003e\n\u003ctd\u003e2025 signal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual platform model: in vivo gene editing and ex vivo CAR T\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences runs on two platforms: ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T. That gives it two revenue and pipeline paths, so it is not tied to one product type or one clinical readout. In Ansoff terms, this is diversification through distinct biotech modalities, with 2 separate technology bases and different risk profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier alliance into solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier’s alliance moves Precision BioSciences, Inc. beyond hematologic cancers into solid tumors, a field that makes up about 90% of adult cancers. That broadens revenue exposure and lowers reliance on one disease area. It also opens a second commercial route for the allogeneic CAR T platform, which could matter if blood-cancer demand stays uneven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiECURE partnership beyond oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc.’s iECURE ARCUS deal pushes the platform beyond oncology and into gene-editing therapy, adding a second therapeutic lane and a different partner-led program model. That broadens the business mix beyond cell therapy and lowers dependence on one disease area. In Ansoff terms, it is diversification with a real shot at spreading pipeline risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eForalumab collaboration as an immunotherapy adjunct\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eForalumab broadens Precision BioSciences beyond CAR T engineering by adding an immunology-led adjunct around lymphodepletion, so the move fits Ansoff diversification rather than pipeline extension. It is a supporting modality, not a direct gene-editing asset, and that lowers product overlap while widening the company’s clinical reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew immunology collaboration\u003c\/li\u003e\n\u003cli\u003eSupports lymphodepletion strategy\u003c\/li\u003e\n\u003cli\u003eExpands beyond core CAR T\u003c\/li\u003e\n\u003cli\u003eDiversifies without direct asset overlap\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline spread across lymphoma, leukemia, myeloma, and solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. has a 4-asset oncology spread across R\/R NHL, R\/R B-ALL, R\/R multiple myeloma, and solid tumors, so one pipeline is not tied to a single market. That mix widens clinical readout paths and partnering options across several cancer segments at once.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 oncology focus areas\u003c\/li\u003e\n\u003cli\u003eBlood cancers plus solid tumors\u003c\/li\u003e\n\u003cli\u003eBroader partner appeal\u003c\/li\u003e\n\u003cli\u003eLower single-indication risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Diversifies Across Four Oncology Lanes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. uses diversification by running ARCUS gene editing and allogeneic CAR T in parallel. That cuts dependence on one product type and one readout.\u003c\/p\u003e\n\u003cp\u003eIts mix now spans 4 oncology lanes: R\/R NHL, R\/R B-ALL, R\/R multiple myeloma, and solid tumors. That widens clinical risk and partner options.\u003c\/p\u003e\n\u003cp\u003eThe Servier and iECURE deals also push the Company into new disease areas and new partner-led models, so the business is less tied to one market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eScope\u003c\/th\u003e\n\u003cth\u003eCount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology focus areas\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore platforms\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew disease reach\u003c\/td\u003e\n\u003ctd\u003eSolid tumors plus gene editing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234293621001,"sku":"dtil-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dtil-ansoff-matrix.webp?v=1785717165","url":"https:\/\/dcfanalyst.com\/products\/dtil-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}